BSEM (BioStem Technologies) Current Deferred Revenue: $0.0 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSEM BioStem Technologies Inc BSEM
36 GF Score
Price $3.29
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies Current Deferred Revenue?

BioStem Technologies BSEM -1.82% 36 Current Deferred Revenue is $0.0 Mil as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

BioStem Technologies's current deferred revenue for the quarter that ended in Sep. 2025 was $0.0 Mil.

BioStem Technologies Current Deferred Revenue Related Terms

BioStem Technologies Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Current Deferred Revenue Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSEM
36GF Score
BioStem Technologies Inc BSEM
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.0 Mil mean?
BioStem Technologies (BSEM) has a Current Deferred Revenue of $0.0 Mil as of Sep. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' Current Deferred Revenue too high?
BioStem Technologies' current Current Deferred Revenue is $0.0 Mil. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Current Deferred Revenue compare to RNTX and SPRO?
BioStem Technologies' Current Deferred Revenue of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Current Deferred Revenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Current Deferred Revenue of $0.0 Mil. The current Current Deferred Revenue is $0.0 Mil. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Current Deferred Revenue is $0.0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score

Get the complete analysis for BSEM

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price